Solifenacin linked QT interval prolongation and torsades de pointes.
作者信息
Bray Jonathan J H, Hancox Jules C
机构信息
School of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University Walk, Bristol, UK.
School of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University Walk, Bristol, BS8 1TD. UK.
出版信息
Ther Adv Drug Saf. 2017 Jul;8(7):245-247. doi: 10.1177/2042098617702616. Epub 2017 Apr 10.
Abstract
摘要
相似文献
1
Solifenacin linked QT interval prolongation and torsades de pointes.索利那新与QT间期延长及尖端扭转型室速有关。
Ther Adv Drug Saf. 2017 Jul;8(7):245-247. doi: 10.1177/2042098617702616. Epub 2017 Apr 10.
2
The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.静脉注射氟哌啶醇对重症患者QT间期离散度的影响：与QT间期延长比较以评估尖端扭转型室速风险
J Clin Pharmacol. 2001 Dec;41(12):1310-8. doi: 10.1177/00912700122012896.
3
Hyperglycemia and subsequent torsades de pointes with marked QT prolongation during refeeding.再喂养期间出现高血糖以及随后伴有显著QT间期延长的尖端扭转型室速。
Nutrition. 2017 Jan;33:145-148. doi: 10.1016/j.nut.2016.05.012. Epub 2016 Jun 5.
4
QT interval prolongation and torsades de pointes due to erythromycin lactobionate.乳糖酸红霉素导致的QT间期延长和尖端扭转型室性心动过速。
Pharmacotherapy. 1995 Nov-Dec;15(6):687-92.
5
K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.K201是一种多通道阻滞剂，可抑制氯非铵诱发的尖端扭转型室速，并减弱复极化的增加。
Eur J Pharmacol. 2007 Jan 19;555(1):54-60. doi: 10.1016/j.ejphar.2006.10.005. Epub 2006 Oct 17.
6
New Generation Antipsychotic Drugs and QTc Interval Prolongation.新一代抗精神病药物与QTc间期延长
Prim Care Companion J Clin Psychiatry. 2003 Oct;5(5):205-215. doi: 10.4088/pcc.v05n0504.
7
Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.医学毒理学家对过量用药患者药物诱导的QT间期延长的实践模式：一项在美国、欧洲和亚太地区开展的调查。
Clin Toxicol (Phila). 2015 May;53(4):204-9. doi: 10.3109/15563650.2015.1013547. Epub 2015 Feb 23.
8
Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms.心电图上QTc延长与尖端扭转型室速的关系：定义与机制。
Am J Cardiol. 1993 Aug 26;72(6):10B-13B. doi: 10.1016/0002-9149(93)90033-9.
9
Long QTc and torsades de pointes in human immunodeficiency virus disease.人类免疫缺陷病毒病中的长QTc间期和尖端扭转型室速
Pacing Clin Electrophysiol. 1997 Nov;20(11):2810-6. doi: 10.1111/j.1540-8159.1997.tb05439.x.
10
A canine model of torsades de pointes.
Pacing Clin Electrophysiol. 1988 Dec;11(12):2235-45. doi: 10.1111/j.1540-8159.1988.tb05990.x.
引用本文的文献
1
Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases.多发性硬化症患者严重药物相互作用的筛查：三个药物相互作用数据库的比较。
Front Pharmacol. 2022 Aug 5;13:946351. doi: 10.3389/fphar.2022.946351. eCollection 2022.
本文引用的文献
1
[Case Report; A case of QT prolongation and torsade de pointes associated with Solifenacin].[病例报告；一例与索利那新相关的QT间期延长和尖端扭转型室性心动过速病例]
Nihon Naika Gakkai Zasshi. 2014 Nov 10;103(11):2804-6. doi: 10.2169/naika.103.2804.
2
Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes.使用FDSS/μCell成像平台对人诱导多能干细胞衍生的心肌细胞中的化合物进行临床前心脏电生理安全性筛选。
J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:217-22. doi: 10.1016/j.vascn.2016.05.009. Epub 2016 May 21.
3
Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.药物诱导的QT间期延长和尖端扭转型室速：药师在风险评估、预防及管理中的作用
Can Pharm J (Ott). 2016 May;149(3):139-52. doi: 10.1177/1715163516641136. Epub 2016 Apr 8.
4
Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.预测不可预测的：药物引起的 QT 间期延长和尖端扭转型室性心动过速。
J Am Coll Cardiol. 2016 Apr 5;67(13):1639-1650. doi: 10.1016/j.jacc.2015.12.063.
5
Frequently occurring Torsades de pointes attacks in an old patient on solifenacin therapy and management strategy.一名老年患者在服用索利那新治疗期间频繁发生尖端扭转型室速发作及处理策略
Anatol J Cardiol. 2015 Apr;15(4):342-3. doi: 10.5152/akd.2015.6121.
6
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).米拉贝隆作为索利那新治疗膀胱过度活动症患者的“附加”疗法的安全性和有效性：日本的一项上市后开放标签研究（MILAI研究）。
BJU Int. 2015 Oct;116(4):612-22. doi: 10.1111/bju.13068. Epub 2015 Apr 23.
7
Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.索利那新与坦索罗辛口服控释系统单片复方制剂治疗男性储尿和排尿下尿路症状的长期安全性和疗效：NEPTUNE 研究和 NEPTUNE II 开放性扩展研究结果。
Eur Urol. 2015 Feb;67(2):262-70. doi: 10.1016/j.eururo.2014.07.013. Epub 2014 Jul 25.
8
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).米拉贝隆与索利那新联合治疗膀胱过度活动症患者的疗效和安全性：一项随机、双盲、剂量范围、2 期研究（Symphony）的结果。
Eur Urol. 2015 Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012. Epub 2014 Feb 19.
9
Solifenacin for overactive bladder: a systematic review and meta-analysis.索利那新用于治疗膀胱过度活动症：一项系统评价与荟萃分析。
Int Urogynecol J. 2012 Aug;23(8):983-91. doi: 10.1007/s00192-011-1641-7. Epub 2012 Feb 7.
10
Aging and Cardiac Fibrosis.衰老与心脏纤维化
Aging Dis. 2011 Apr;2(2):158-173.
Zotero 插件